|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Jul 8, 2009. Podium presentation: Use of a
claims database to estimate AD severity and costs by severity level
Monday,
July 13, 10:30 -12:30 PM
Poster
P2-066: Web-Based Application to Estimate and Project the Burden of Alzheimer’s
Disease and Evaluate the Impact of Potential Interventions
Monday,
July 13, 12:30 - 2:30 PM
Poster
P2-071: Increased Risk of Serious Co-Morbidities in a Cohort of AD Patients
Compared to a Similar Non-AD Cohort
Monday,
July 13, 12:30- 2:30 PM
Poster
P3-113: Hip Fracture Risk and Subsequent Mortality among Alzheimer’s Disease
Patients in the United Kingdom, 1988-2007
Tuesday,
July 14, 12:30- 3:00 PM
Poster
P3-221: Predicting Costs of Care for Unique Dependence Levels in Patients with
Alzheimer’s Disease
Tuesday,
July 14, 12:30 -2:30 PM
Presentations
of Bapineuzumab
Poster
P3-246: Pharmacokinetics and Pharmacodynamics of Bapineuzumab Following Multiple
Intravenous Infusions in Patients with Mild-to-Moderate Alzheimer's
Disease
Tuesday,
July 14, 12:30 -2:30 PM
2
Presentations
of ELND005 (AZD-103)
Poster
P2-082: Oral Amyloid Anti-Aggregating Agent ELND005 is Measurable in CSF and
Brain of Healthy Adult Men
Monday,
July 13, 12:30 - 3:00 PM
Poster
P2-082: Defining Mild Cognitive Impairment: Disparity of Incidence and
Prevalence Estimates with Variable Operationalized Definitions
Monday,
July 13, 12:30- 2:30 PM
Poster
P2-225: Characterization of Inositol Transporters as a Method for Drug Delivery
to the CNS
Monday,
July 13, 12:30 - 3:00 PM
Poster
P3-245: A Sensitive Assay Measuring the Binding of Amyloid Beta Monomers to
Aggregates Reveals the Potential of ELND005 (scylloinositol) to Reduce and
Reverse Amyloid Accumulation
Tuesday,
July 14, 12:30 - 3:00 PM
Poster P3-258: The
effect of scyllo-inositol derivatives on β-amyloid peptide
aggregation
Tuesday,
July 14, 12:30 - 3:00 PM
Poster
P3-279: Scyllo-Inositol (ELND005) Ameliorates Amyloid Pathology in an Aggressive
Mouse Model of Alzheimer’s Disease
Tuesday,
July 14, 12:30 - 3:00 PM
Poster
P3-286: Biophysical Characterization of Scyllo-Inositol-Aβ
Interactions
Tuesday,
July 14, 12:30 - 3:00 PM
Poster
P4-193: Quantification of Cholinergic Degradation and Adult Neurogenesis in
TgCRND8 Mice Following Treatment with Scyllo-Inositol (ELND005)
Wednesday,
July 15, 12:30 - 3:00 PM
Poster
P4-354: ELND005 (scyllo-inositol), the β-Amyloid Anti-Aggregation Therapeutic,
Demonstrates Robust Brain Uptake in Rats Following Oral
Administration
Wednesday,
July 15, 12:30 - 3:00 PM
Presentations
of Gamma Secretase Inhibitors (or other Elan Research)
Poster
P1-035: Pharmacokinetic and pharmacodynamic Analysis of a Novel Gamma Secretase
Inhibitor in a Non-Transgenic A-Beta Mouse Efficacy Model
Sunday,
Jul 12, 2009, 12:30 - 3:00 PM
About
Alzheimer’s Disease
Alzheimer’s
disease, a leading cause of dementia, is a progressive brain disorder that
gradually destroys a person's memory and ability to learn, reason, make
judgments, communicate and carry
3
out daily
activities. Alzheimer’s disease may result from the build-up of toxic
beta-amyloid peptides in the brain. As Alzheimer’s disease progresses,
individuals may also experience changes in personality and behavior, such as
anxiety, suspiciousness or agitation, as well as delusions or hallucinations. It
is currently estimated that more than 5 million Americans have Alzheimer’s
disease and more than 24 million people worldwide over the age of 60 have some
form of dementia (Source: Alzheimer’s Association and Alzheimer’s Disease
International).
About
Elan
Elan
Corporation, plc is a neuroscience-based biotechnology company committed to
making a difference in the lives of patients and their families by dedicating
itself to bringing innovations in science to fill significant unmet medical
needs that continue to exist around the world. Elan shares trade on the New
York, London and Dublin Stock Exchanges. For additional information about the
company, please visit http://www.elan.com.
|
| |||||||
